InspireMD
TEL AVIV, Israel, March 2, 2011 - InspireMD (www.inspire-md.com/site_en/), developer of
the MGuard(TM) net protective stent system (
www.inspire-md.com/site_en/mguard/the-technology/), has expanded its
MGuard production facilities to meet the steady increase in demand.
TEL AVIV, Israel, December 17, 2010 - InspireMD, developer of the novel MGuard(TM), a combination of
a coronary stent merged with an embolic protection specifically designed for
Acute MI (AMI) patients, received significant exposure at the ICI,
Innovations in Interventional Cardiology, meeting this week in Tel-Aviv.
TEL AVIV, Israel, September 9, 2010 - InspireMD Ltd., a medical device company engaged in the development and
commercialization of the mesh based MGuard(TM) stent systems, is proud to
report that mesh-based protection, is now recommended for use in the new
Guidelines of the Task force of Myocardial Revascularization of the European
Society of Cardiology (ESC).
PARIS, May 26, 2010 - InspireMD, Ltd.
SAN FRANCISCO - InspireMD, developers of MGuard(TM), announced today that the first patient has been enrolled in the Israeli MGuard(TM) Registry.
More News
- InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR ‘09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Leon MD
- InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
